nach oben

Seminars in Immunopathology

Erschienen in:

01.03.2013 | Review

The role of PGE₂-associated inflammatory responses in gastric cancer development

verfasst von: Hiroko Oshima, Masanobu Oshima

Erschienen in: Seminars in Immunopathology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Accumulating evidence indicates that inflammation plays a critical role in cancer development. Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme for prostanoid biosynthesis, including prostaglandin E₂ (PGE₂), and plays a key role in both inflammation and cancer. It has been demonstrated that inhibition of COX-2 and PGE₂ receptor signaling results in the suppression of tumor development in a variety of animal models. However, the molecular mechanisms underlying COX-2/PGE₂-associated inflammation in carcinogenesis have not yet been fully elucidated. In order to study the role of PGE₂-associated inflammatory responses in tumorigenesis, it is important to use in vivo mouse models that recapitulate human cancer development from molecular mechanisms with construction of tumor microenvironment. We have developed a gastritis model (K19-C2mE mice) in which an inflammatory microenvironment is constructed in the stomach via induction of the COX-2/PGE₂ pathway. We also developed a gastric cancer mouse model (Gan mice) in which the mice develop inflammation-associated gastric tumors via activation of both the COX-2/PGE₂ pathway and Wnt signaling. Expression analyses using these in vivo models have revealed novel mechanisms of the inflammatory responses underlying gastric cancer development. PGE₂-associated inflammatory responses activate epidermal growth factor receptor (EGFR) signaling through the induction of EGFR ligands and ADAMs that release EGFR ligands from the cell membrane. In Gan mice, a combination treatment with EGFR and COX-2 inhibitors significantly suppresses gastric tumorigenesis. Moreover, PGE₂-associated inflammation downregulates tumor suppressor microRNA, miR-7, in gastric cancer cells, which suppresses epithelial differentiation. These results indicate that PGE₂-associated inflammatory responses promote in vivo gastric tumorigenesis via several different molecular mechanisms.

Kuper H, Adami HO, Trichopoulos D (2000) Infections as a major preventable cause of human cancer. J Intern Med 248:171–183PubMedCrossRef

Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044PubMedCrossRef

Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKβ- and JNK1-dependent inflammation. Cancer Cell 17:89–97PubMedCrossRef

Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197–208PubMedCrossRef

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRef

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899PubMedCrossRef

Wang D, DuBois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181–193PubMedCrossRef

Wang D, DuBois RN (2010) The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29:781–788PubMedCrossRef

10.

Li HJ, Reinhardt F, Herschman HR, Weinberg RA (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem-cell niche via prostaglandin E₂ signaling. Cancer Discov 2:840–855

11.

Oshima H, Oguma K, Du YC, Oshima M (2009) Prostaglandin E₂, Wnt, and BMP in gastric tumor mouse models. Cancer Sci 100:1779–1785PubMedCrossRef

12.

Oshima H, Oshima M (2010) Mouse models of gastric tumors: Wnt activation and PGE₂ induction. Pathol Int 60:599–607PubMedCrossRef

13.

Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596PubMedCrossRef

14.

Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614PubMedCrossRef

15.

Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedCrossRef

16.

Oshima M, Taketo MM (2002) COX selectivity and animal models for colon cancer. Curr Pharm Des 8:1021–1034PubMedCrossRef

17.

Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in Apc^∆716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedCrossRef

18.

Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000) Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705–4708PubMed

19.

Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, Subbaramaiah K (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7:2669–2674PubMed

20.

van Rees BP, Sivula A, Thoren S, Yokozaki H, Jalobsson PJ, Offerhaus GJ, Ristimaki A (2003) Expression of microsomal prostaglandin E synthase-1 in intestinal gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 107:551–556PubMedCrossRef

21.

Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68:3251–3259PubMedCrossRef

22.

Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vella AT, Rosenberg DW (2011) Selective PGE₂ suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res 4:1198–1208CrossRef

23.

Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Natumiya S, Oshima M, Taketo MM (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc^∆716 knockout mice. Nat Med 7:1048–1051PubMedCrossRef

24.

Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S, Taketo MM (2002) Cyclooxygenase 2- and prostaglandin E₂ receptor EP₂-dependent angiogenesis in Apc^∆716 mouse intestinal polyps. Cancer Res 62:506–511PubMed

25.

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E₂ promotes colon cancer cell growth through a G_s-axin–β-catenin signaling axis. Science 310:1504–1510PubMedCrossRef

26.

Balkwill F (2009) Tumor necrosis factor and cancer. Nat Rev Cancer 9:361–371PubMedCrossRef

27.

Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999) Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 5:828–831PubMedCrossRef

28.

Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR (2004) Expression of both TNF-α receptor subtypes is essential for optimal skin tumor development. Oncogene 23:1902–1910PubMedCrossRef

29.

Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N (2008) Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560–570PubMed

30.

Oshima H, Oshima M (2012) The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol 47:97–106PubMedCrossRef

31.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296PubMedCrossRef

32.

Heikkila K, Ebrahim S, Lawlor DA (2008) Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 44:937–945PubMedCrossRef

33.

Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitala S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR (2009) gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:91–102PubMedCrossRef

34.

Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M (2009) IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113PubMedCrossRef

35.

Gregorieff A, Clevers H (2005) Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 19:877–890PubMedCrossRef

36.

Taketo MM (2006) Wnt signaling and gastrointestinal tumorigenesis in mouse models. Oncogene 25:7522–7530PubMedCrossRef

37.

Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M (1995) Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 92:4482–4486PubMedCrossRef

38.

Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM (1999) Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 18:5931–5942PubMedCrossRef

39.

Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J, Lowy AM (2002) β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 62:3503–3506PubMed

40.

Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH (2001) Altered expression and mutation of β-catenin gene in gastric carcinomas and cell lines. Int J Cancer 95:108–113PubMedCrossRef

41.

Cheng XX, Wang ZC, Chen XY, Sun Y, Kong QY, Liu J, Li H (2005) Correlation of Wnt-2 expression and β-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination. Cancer Lett 223:339–347PubMedCrossRef

42.

Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M (2006) Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E₂ pathway. Gastroenterology 131:1086–1095PubMedCrossRef

43.

Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY (1999) Frequent somatic mutations of the β-catenin gene in intestinal-type gastric cancer. Cancer Res 59:4257–4260PubMed

44.

Ebert MP, Fei G, Kahmann S, Muller O, Yu J, Sung JJ, Malfertheiner P (2002) Increased β-catenin mRNA levels and mutational alterations of the APC and β-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23:87–91PubMedCrossRef

45.

Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, Hirao A, Saya H, Taketo MM, Oshima M (2008) Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells. EMBO J 27:1671–1681PubMedCrossRef

46.

Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57:1276–1280PubMed

47.

Al-Marhoon MS, Nunn S, Soames RW (2004) CagA + Helicobacter pylori induces greater levels of prostaglandin E2 than cagA − strains. Prostaglandins Other Lipid Mediat 73:181–189PubMedCrossRef

48.

Sun WH, Yu Q, Shen H, Qu XL, Cao DZ, Yu T, Qian C, Zhu F, Sun YL, Fu XL, Su H (2004) Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J Gastroenterol 10:2809–2813PubMed

49.

Oshima H, Oshima M, Inaba K, Taketo MM (2004) Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 23:1669–1678PubMedCrossRef

50.

Oshima M, Ohima H, Matsunaga A, Taketo MM (2005) Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-α-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice. Cancer Res 65:9147–9151PubMedCrossRef

51.

Yamaguchi H, Goldenring JR, Kaminishi M, Lee JR (2002) Identification of spasmolytic polypeptide-expressing metaplasia (SPEM) in remnant gastric cancer and surveillance post-gastrectomy biopsies. Dig Dis Sci 47:573–578PubMedCrossRef

52.

Halldorsdottir AM, Sigurdardottrir M, Jonasson JG, Oddsdottir M, Magnusson J, Lee JR, Goldenring JR (2003) Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci 48:431–441PubMedCrossRef

53.

Goldenring JR, Nomura S (2009) Insight into the development of preneoplastic metaplasia: spasmolytic polypeptide-expressing metaplasia and oxyntic atrophy. In: Wang TC, Fox JG, Giraud AS (eds) The biology of gastric cancer. Springer, New York, pp 361–375CrossRef

54.

Nomura S, Baxter T, Yamaguchi H, Leys C, Vartapetian AB, Fox JG, Lee JR, Wang TC, Goldenring JR (2004) Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology 127:582–594PubMedCrossRef

55.

Kang W, Rathinavelu S, Samuelson LC, Merchang JL (2005) Interferon γ induction of gastric mucous neck cell hypertrophy. Lab Invest 85:702–715PubMedCrossRef

56.

Judd LM, Alderman BM, Howlett M, Shulkes A, Dow C, Moverley J, Grail D, Jenkins BJ, Ernst M, Giraud AS (2004) Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 126:196–207PubMedCrossRef

57.

Guo X, Oshima H, Kitamura T, Taketo MM, Oshima M (2008) Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem 283:19864–19871PubMedCrossRef

58.

Itadani H, Oshima H, Oshima M, Kotani H (2009) Mouse gastric tumor models with prostaglandin E₂ pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics 10:615PubMedCrossRef

59.

Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba E, Saya H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of xc⁻ and thereby promotes tumor growth. Cancer Cell 19:387–400PubMedCrossRef

60.

Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O (2010) CD44(+) slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E₂ in gastric tumorigenesis. Cancer Sci 101:673–678PubMedCrossRef

61.

Oshima H, Hioki K, Popivanova BK, Oguma K, van Rooijen N, Ishikawa T, Oshima M (2011) Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 140:596–607PubMedCrossRef

62.

Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229–241PubMedCrossRef

63.

Rakoff-Nahoum S, Medzhitov R (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124–127PubMedCrossRef

64.

Chinen T, Komai K, Muto G, Morita R, Inoue N, Yoshida H, Sekiya T, Yoshida R, Nakamura K, Takayanagi R, Yoshimura A (2010) Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nature Commun 2:190CrossRef

65.

Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005) Cyclooxigenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2:254–266CrossRef

66.

Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW (2002) Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99:1521–1526PubMedCrossRef

67.

Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2006) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024–1028

68.

Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN (2008) Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 67:9380–9388CrossRef

69.

Buchanan FG, Wang D, Bargiacchi F, DuBois RN (2003) Prostaglandin E₂ regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278:35451–35457PubMedCrossRef

70.

Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN (2006) Role of β-arrestin1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103:1492–1497PubMedCrossRef

71.

Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS (2002) Prostaglandin E₂ transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289–293PubMedCrossRef

72.

Shao J, Lee SB, Guo H, Evers BM, Sheng H (2003) Prostaglandin E₂ stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63:5218–5223PubMed

73.

Subbaramaiah K, Benezra R, Hudis C, Dannenberg AJ (2008) Cyclooxygenase-2-derived prostaglandin E₂ stimulates Id-1 transcription. J Biol Chem 283:33955–33968PubMedCrossRef

74.

Al-Salihi MA, Ulmer SC, Doan T, Nelson CD, Crotty T, Prescott SM, Stafforini DM, Topham MK (2007) Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-α converting enzyme. Cell Signal 19:1956–1963PubMedCrossRef

75.

Oshima H, Popivanova BK, Oguma K, Dong D, Ishikawa T, Oshima M (2011) Activation of epidermal growth factor receptor signaling by the prostaglandin E₂ receptor EP4 pathway during gastric tumorigenesis. Cancer Sci 102:713–719PubMedCrossRef

76.

Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98:621–628PubMedCrossRef

77.

Oshima H, Itadani H, Kotani H, Taketo MM, Oshima M (2009) Induction of prostaglandin E₂ pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res 69:2729–2733PubMedCrossRef

78.

Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127–137PubMedCrossRef

79.

Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, Dey SK, DuBois RN (2006) Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E₂ and promotes cancer progression. Cancer Res 66:6649–6656PubMedCrossRef

80.

Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103:12098–12102PubMedCrossRef

81.

Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355PubMedCrossRef

82.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297PubMedCrossRef

83.

Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269PubMedCrossRef

84.

Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136:586–591PubMedCrossRef

85.

Di Leva G, Croce CM (2010) Roles of small RNAs in tumor formation. Trends Mol Med 16:257–267PubMedCrossRef

86.

Sonkoly E, Pivarcsi A (2011) MicroRNAs in inflammation and response to injuries induced by environmental pollution. Mutat Res 717:46–53PubMedCrossRef

87.

O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604–1609PubMedCrossRef

88.

Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM (2007) Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179:5082–5089PubMed

89.

Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39:493–506PubMedCrossRef

90.

Kong D, Piao YS, Yamashita S, Oshima H, Oguma K, Fushida S, Fujimura T, Minamoto T, Seno H, Yamada Y, Satou K, Ushijima T, Ishikawa T, Oshima M (2012) Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene 31:3949–3960PubMedCrossRef

91.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257–2261PubMedCrossRef

92.

Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106:3207–3212PubMedCrossRef

93.

Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B (2008) MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68:3566–3572PubMedCrossRef

94.

Reddy SD, Ohshiro K, Rayala SK, Kumar R (2008) MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 68:8195–8200PubMedCrossRef

95.

Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284:5731–5741PubMedCrossRef

96.

Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A, Wang A, Dai Y, Zhou X (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432:199–205PubMedCrossRef

97.

Saydam O, Senol O, Wurdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, Brenner GJ, Breakefield XO (2011) miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 71:852–861PubMedCrossRef

Titel: The role of PGE2-associated inflammatory responses in gastric cancer development
verfasst von: Hiroko Oshima
Masanobu Oshima
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 2/2013
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-012-0353-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis

Introduction for inflammation and cancer

Helicobacter pylori infection and gastric carcinogenesis in rodent models

Resolution of inflammation as a novel chemopreventive strategy

Inflammation and colorectal cancer: colitis-associated neoplasia